NT-proBNP in monitoring treatment of patients with congestive heart failure

Clinical Laboratory

Volumn 53, Issue 1-2, 2007, Pages 35-39

  Al Meslmani, Bssam Mohamad ^a   Fahoum, Sahar K ^a   Shamia, Marwan G ^a  

^a DAMASCUS UNIVERSITY   (Syrian Arab Republic)

Author keywords

Congestive heart failure; Echocardiography; Ejection fraction; NT proBNP; NYHA classification

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CAPTOPRIL; DIGOXIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; ISOSORBIDE DINITRATE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHEMOLUMINESCENCE; CONGESTIVE HEART FAILURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROIMMUNOASSAY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART VENTRICLE OVERLOAD; HUMAN; MAJOR CLINICAL STUDY; PATIENT MONITORING; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; STUDENT T TEST; SYRIAN ARAB REPUBLIC;

ADULT; AGED; AGED, 80 AND OVER; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SYRIA; TREATMENT OUTCOME;

EID: 33847642047     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Shapiro BP, Chen HH, Burnett JC Jr, and Redfield MM. Use of plasma brain nutriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clin Proc 2003: 78: 481-6
2. Francis G. Gassler J, Sonnenblick E. Pathophysiology and diagnosis of heart failure. In: Fuster V, Alexander W. Rourke R (eds) The Heart, 10th ed. McGraw-Hill, 2001: 655-686
3. Braunmald E. Colucci W, Grossman W. Clinical aspects of heart failure. In: Braunwald E (ed) Heart Disease, 5th ed. W.B. Saunders, 1997: 445-470
4. Hudson A, McAnaw J, Reid F. Congestive heart failure. In: Walker R, Edwards C (eds) Clinical Pharmacy and Therapeutics, 3rd ed. Churchill Livingstone 2003: 299-319
5. Katzung B, Parmley W. Drugs used in congestive heart failure. In: Katzung B (ed) Basic & Clinical Pharmacology, 8th ed. McGraw-Hill 2001: 200-290
6. Nalkagawa O, Ogawa Y, Itoh H, Suga S, Koruatsu Y, Kishimoto I, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypcrtrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995; 96: 1280-7
7. Macda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-32
8. Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: are they merely markers of cardiac disease? Clin Chem Lab Med 2002; 40: 752-60
9. Pelletier C. Medications affecting cardiac and renal function. In: Pelletier C (ed) Pharmacology, McGraw-Hill, 2003: 185-225
10. Lejemtel T. Sonnenblick E, Frishman W. Management of heart failure. In: Fuster V, Alexander W, Rourke R (eds) The Heart, 10th ed. McGraw-Hill, 2001: 687-724
11. Johnson W, Omland T, Hall C, Lucas C, Myking OL, Collins C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002; 39: 1623-9
12. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and mnorbidity in the Valsartan Heart Failure Trial (Val-HeFT). 2003. 107: 1278-83
13. Weber M, Dill T, Deetjen A, Neumann T, Ekinci O, Hansel J et al. Left ventricular adaptation after atrial septal defect closure assessed by increased concentrations of N-terminal pro-brain natriuretic peptide and cardiac magnetic resonance imaging in adult patients. Heart 2006; 92: 671-5